Press Enter to search · Esc to close
A new wave of peer-reviewed evidence shows GLP-1 drugs reaching further into metabolic medicine—while exposing risks that busy men should know before they fill the prescription.
A wave of 2025 reviews and trial analyses sketches what comes after tirzepatide — broader populations, bigger weight-loss numbers, and tentative steps into autoimmune diabetes.
Three new reviews argue we've been measuring the wrong thing. The real target isn't weight — it's the adipose tissue quietly running your metabolism.
A major new synthesis argues obesity is not just a metabolic condition but a fundamentally altered immunological state — reshaping how we think about GLP-1s, weight loss, and the body's defenses.
A new wave of 2025 research suggests semaglutide and its siblings do far more than shrink waistlines. The evidence is moderate, the implications are not.
New 2025 data hints that GLP-1 drugs may quiet inflammation in the liver and skin — but a sober pharmacology review reminds us the price tag, and the science, are still catching up.
Two fresh analyses push the GLP-1 conversation past nausea, flagging ear-nose-throat signals and a higher risk of failed bowel prep. Here's what tired parents juggling a new prescription actually need to know.
A three-year cohort of type 2 diabetics tracked who silently progressed to liver fibrosis — and which routine lab markers offered the earliest warning.
As GLP-1 demand outpaces supply, fresh data from Karachi, a critical review of Asian-descent dosing, and an early trial of a novel Chinese molecule hint at a more personalized future for metabolic care.
A small real-world study suggests older, cheaper anti-obesity pills may help preserve much of the weight loss achieved on a year of GLP-1s — a practical lifeline as access and prices stay volatile.